RemeGen
PublicRemeGen is now publicly traded
The data on this page reflects RemeGen's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Nov 9, 2020
Last Round
Follow-on Offering
Mar 31, 2022
Total Funding Raised
$1.03B
Company Overview
RemeGen is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative biologic drugs for the treatment of autoimmune, oncology, and ophthalmic diseases.
Sector
Healthcare
AI Layer
Non-AI
Keywords
RemeGen Comparables
Compare RemeGen with similar companies based on industry and business-model similarity.
No public comparables are available for RemeGen. Request access to learn about comparables coverage.
Book a demoFor institutional investors. Book with your work email.
RemeGen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Mar 31, 2022 | ||||
| IPO | Nov 9, 2020 | ||||
| Private Equity | Mar 16, 2020 |
For institutional investors. Book with your work email.
RemeGen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loyal Valley Capital | Private Equity |
| Lake Bleu Capital | IPO, Private Equity |
| Huatai International | IPO |
| Hillhouse Capital Group | IPO |
| OrbiMed | Private Equity, IPO |
| Morgan Stanley | IPO |
| Janchor Partners | Private Equity |
For institutional investors. Book with your work email.
RemeGen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.